Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 49.06
(-1.57%)
EUR 49.06
(-1.57%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 21.31 Million EUR | 175.99% |
| 2022 | -52.77 Million EUR | -103.99% |
| 2021 | -25.87 Million EUR | -221.58% |
| 2020 | 21.28 Million EUR | 22.45% |
| 2019 | 17.37 Million EUR | 128.36% |
| 2018 | -61.28 Million EUR | -5369.73% |
| 2017 | 1.16 Million EUR | 113.05% |
| 2016 | -8.91 Million EUR | -271.29% |
| 2015 | -2.4 Million EUR | -124.91% |
| 2014 | 9.63 Million EUR | -16.77% |
| 2013 | 11.57 Million EUR | 169.8% |
| 2012 | -16.58 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 68.68 Million EUR | 71.27% |
| 2024 Q2 | 59.12 Million EUR | 11.49% |
| 2023 FY | 40.1 Million EUR | 175.99% |
| 2023 Q2 | -87.31 Million EUR | -21.0% |
| 2023 Q1 | -72.15 Million EUR | -36.72% |
| 2023 Q3 | 7.27 Million EUR | 108.34% |
| 2023 Q4 | 40.1 Million EUR | 450.97% |
| 2022 Q2 | -84.49 Million EUR | -186.98% |
| 2022 FY | -52.77 Million EUR | -103.99% |
| 2022 Q4 | -52.77 Million EUR | -119.75% |
| 2022 Q3 | -24.01 Million EUR | 71.58% |
| 2022 Q1 | -29.44 Million EUR | -13.8% |
| 2021 Q2 | -53.91 Million EUR | -53479.21% |
| 2021 Q1 | 101 Thousand EUR | -99.45% |
| 2021 Q4 | -25.87 Million EUR | 64.1% |
| 2021 Q3 | -72.06 Million EUR | -33.68% |
| 2021 FY | -25.87 Million EUR | -221.58% |
| 2020 Q4 | 18.21 Million EUR | -54.03% |
| 2020 FY | 21.28 Million EUR | 22.45% |
| 2020 Q3 | 39.61 Million EUR | -0.78% |
| 2020 Q2 | 39.92 Million EUR | 92.69% |
| 2020 Q1 | 20.72 Million EUR | 48.87% |
| 2019 Q2 | -21.31 Million EUR | 5.91% |
| 2019 Q4 | 13.91 Million EUR | 882.41% |
| 2019 Q1 | -22.65 Million EUR | 63.03% |
| 2019 FY | 17.37 Million EUR | 128.36% |
| 2019 Q3 | -1.77 Million EUR | 91.65% |
| 2018 Q1 | 1.45 Million EUR | -42.65% |
| 2018 Q3 | 22.04 Million EUR | 159.59% |
| 2018 Q2 | 8.49 Million EUR | 483.64% |
| 2018 FY | -61.28 Million EUR | -5369.73% |
| 2018 Q4 | -61.28 Million EUR | -378.02% |
| 2017 Q4 | 2.53 Million EUR | -13.5% |
| 2017 FY | 1.16 Million EUR | 113.05% |
| 2017 Q3 | 2.93 Million EUR | 158.81% |
| 2017 Q2 | -4.98 Million EUR | -237.08% |
| 2017 Q1 | 3.63 Million EUR | 147.97% |
| 2016 FY | -8.91 Million EUR | -271.29% |
| 2016 Q3 | -3.09 Million EUR | 36.74% |
| 2016 Q2 | -4.89 Million EUR | -423.48% |
| 2016 Q1 | 1.51 Million EUR | -88.82% |
| 2016 Q4 | -7.58 Million EUR | -145.12% |
| 2015 Q1 | 8.08 Million EUR | -16.1% |
| 2015 FY | -2.4 Million EUR | -124.91% |
| 2015 Q4 | 13.52 Million EUR | -27.16% |
| 2015 Q3 | 18.57 Million EUR | 98.31% |
| 2015 Q2 | 9.36 Million EUR | 15.83% |
| 2014 Q2 | -5000.00 EUR | -100.03% |
| 2014 Q1 | 17.36 Million EUR | 49.97% |
| 2014 FY | 9.63 Million EUR | -16.77% |
| 2014 Q4 | 9.63 Million EUR | 6.44% |
| 2014 Q3 | 9.05 Million EUR | 181140.0% |
| 2013 Q3 | 14.46 Million EUR | 49.2% |
| 2013 FY | 11.57 Million EUR | 169.8% |
| 2013 Q4 | 11.57 Million EUR | -19.95% |
| 2013 Q1 | 15.89 Million EUR | 195.84% |
| 2013 Q2 | 9.69 Million EUR | -39.02% |
| 2012 Q4 | -16.58 Million EUR | 0.0% |
| 2012 FY | -16.58 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Boiron SA | -60.34 Million EUR | 135.32% |
| Vetoquinol SA | -129.83 Million EUR | 116.415% |
| Valneva SE | 82.73 Million EUR | 74.24% |
| AB Science S.A. | 13.03 Million EUR | -63.506% |
| Nanobiotix S.A. | -29.8 Million EUR | 171.52% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | 7850.182% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 215.056% |
| BioSenic S.A. | 28.04 Million EUR | 24.002% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 110.848% |
| Formycon AG | 2.45 Million EUR | -769.563% |